These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 22699315)

  • 21. Why do some trauma patients die while others survive? A matched-pair analysis based on data from Trauma Register DGU®.
    Bieler D; Paffrath T; Schmidt A; Völlmecke M; Lefering R; Kulla M; Kollig E; Franke A;
    Chin J Traumatol; 2020 Aug; 23(4):224-232. PubMed ID: 32576425
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The use of recombinant activated factor VII (rFVIIa) in the management of patients with major haemorrhage in military hospitals over the last 5 years.
    Smith JE
    Emerg Med J; 2013 Apr; 30(4):316-9. PubMed ID: 22609697
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The treatment of bleeding is to stop the bleeding! Treatment of trauma-related hemorrhage.
    Boffard KD; Choong PI; Kluger Y; Riou B; Rizoli SB; Rossaint R; Warren B;
    Transfusion; 2009 Dec; 49 Suppl 5():240S-7S. PubMed ID: 19954486
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Recombinant factor VIIa as adjunctive therapy for bleeding control in severely injured trauma patients: two parallel randomized, placebo-controlled, double-blind clinical trials.
    Boffard KD; Riou B; Warren B; Choong PI; Rizoli S; Rossaint R; Axelsen M; Kluger Y;
    J Trauma; 2005 Jul; 59(1):8-15; discussion 15-8. PubMed ID: 16096533
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Recombinant activated factor VII in controlling bleeding in non-hemophiliac patients.
    AlGahtani FH; Alshaikh M; AlDiab A
    Ann Saudi Med; 2010; 30(3):198-202. PubMed ID: 20427935
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of recombinant activated Factor VII for refractory after lung transplant bleeding as an effective strategy to restrict blood transfusion and associated complications.
    Bhaskar B; Zeigenfuss M; Choudhary J; Fraser JF
    Transfusion; 2013 Apr; 53(4):798-804. PubMed ID: 22845023
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recombinant factor VIIa for the correction of coagulopathy before emergent craniotomy in blunt trauma patients.
    Brown CV; Foulkrod KH; Lopez D; Stokes J; Villareal J; Foarde K; Curry E; Coopwood B
    J Trauma; 2010 Feb; 68(2):348-52. PubMed ID: 20154547
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gender-specific differences in severely injured patients between 2002 and 2011: data analysis with matched-pair analysis.
    Schoeneberg C; Kauther MD; Hussmann B; Keitel J; Schmitz D; Lendemans S
    Crit Care; 2013 Nov; 17(6):R277. PubMed ID: 24289182
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Does the presence of an emergency physician influence pre-hospital time, pre-hospital interventions and the mortality of severely injured patients? A matched-pair analysis based on the trauma registry of the German Trauma Society (TraumaRegister DGU
    Bieler D; Franke A; Lefering R; Hentsch S; Willms A; Kulla M; Kollig E;
    Injury; 2017 Jan; 48(1):32-40. PubMed ID: 27586065
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Recombinant factor VIIa: decreasing time to intervention in coagulopathic patients with severe traumatic brain injury.
    Stein DM; Dutton RP; Kramer ME; Handley C; Scalea TM
    J Trauma; 2008 Mar; 64(3):620-7; discussion 627-8. PubMed ID: 18332801
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of recombinant factor VIIa treatment for massive hemorrhage in patients with multiple traumas.
    Koh YR; Cho SJ; Yeom SR; Chang CL; Lee EY; Son HC; Kim HH
    Ann Lab Med; 2012 Mar; 32(2):145-52. PubMed ID: 22389882
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Investigation of outcomes following recombinant activated FVII use for refractory bleeding during abdominal aortic aneurysm repair.
    Kandane-Rathnayake RK; Willis CD; Beiles CB; Bourke BM; Cameron PA; McCall P; Phillips LE
    Eur J Vasc Endovasc Surg; 2013 Jun; 45(6):617-25. PubMed ID: 23433950
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safe use of recombinant activated factor VIIa for recalcitrant postoperative haemorrhage in cardiac surgery.
    Tatoulis J; Theodore S; Meswani M; Wynne R; Hon-Yap C; Powar N
    Interact Cardiovasc Thorac Surg; 2009 Sep; 9(3):459-62. PubMed ID: 19542087
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recombinant activated factor VII for refractory bleeding after cardiac surgery--a retrospective analysis of safety and efficacy.
    von Heymann C; Redlich U; Jain U; Kastrup M; Schroeder T; Sander M; Grosse J; Ziemer S; Koscielny J; Konertz WF; Wernecke KD; Spies C
    Crit Care Med; 2005 Oct; 33(10):2241-6. PubMed ID: 16215377
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The use of recombinant activated factor VII in trauma patients: Experience from the Australian and New Zealand haemostasis registry.
    Cameron P; Phillips L; Balogh Z; Joseph A; Pearce A; Parr M; Jankelowitz G
    Injury; 2007 Sep; 38(9):1030-8. PubMed ID: 17706654
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of recombinant factor VIIa as an adjunctive therapy in damage control for wartime vascular injuries: a case control study.
    Fox CJ; Mehta SG; Cox ED; Kragh JF; Salinas J; Holcomb JB
    J Trauma; 2009 Apr; 66(4 Suppl):S112-9. PubMed ID: 19359954
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Does increased prehospital replacement volume lead to a poor clinical course and an increased mortality? A matched-pair analysis of 1896 patients of the Trauma Registry of the German Society for Trauma Surgery who were managed by an emergency doctor at the accident site.
    Hussmann B; Lefering R; Waydhas C; Touma A; Kauther MD; Ruchholtz S; Lendemans S;
    Injury; 2013 May; 44(5):611-7. PubMed ID: 22377276
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety of rFVIIa in hemodynamically unstable polytrauma patients with traumatic brain injury: post hoc analysis of 30 patients from a prospective, randomized, placebo-controlled, double-blind clinical trial.
    Kluger Y; Riou B; Rossaint R; Rizoli SB; Boffard KD; Choong PI; Warren B; Tillinger M
    Crit Care; 2007; 11(4):R85. PubMed ID: 17686152
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Possible role of recombinant activated factor VII (rFVIIa) in the control of hemorrhage associated with massive trauma.
    Martinowitz U; Kenet G; Lubetski A; Luboshitz J; Segal E
    Can J Anaesth; 2002 Dec; 49(10):S15-20. PubMed ID: 12546003
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Low-dose recombinant factor VIIa for massive bleeding: a single centre observational cohort study with 73 patients.
    Schmid P; Mordasini A; Luginbühl M; Regli B; Kohler HP; Zimmermann H; Inderbitzin D; Hirt A; Lämmle B; Alberio L
    Swiss Med Wkly; 2011; 141():w13213. PubMed ID: 21735365
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.